Century Therapeutics, Inc. (NASDAQ:IPSC) Receives Average Rating of “Hold” from Analysts

Century Therapeutics, Inc. (NASDAQ:IPSC) has received a consensus recommendation of “Hold” from the seven research firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $4.75.

IPSC has been the topic of a number of analyst reports. Leerink Partners set a $2.00 price target on Century Therapeutics and gave the stock a “market perform” rating in a research report on Friday, March 13th. Mizuho began coverage on Century Therapeutics in a research note on Wednesday, May 27th. They set an “outperform” rating and a $8.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Century Therapeutics in a research note on Monday, April 6th. TD Cowen began coverage on Century Therapeutics in a research note on Wednesday, February 25th. They set a “buy” rating for the company. Finally, Wall Street Zen upgraded Century Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, May 24th.

Institutional Investors Weigh In On Century Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in IPSC. Bank of America Corp DE lifted its stake in Century Therapeutics by 109.1% during the fourth quarter. Bank of America Corp DE now owns 66,043 shares of the company’s stock worth $67,000 after purchasing an additional 34,466 shares during the last quarter. AQR Capital Management LLC lifted its stake in Century Therapeutics by 358.9% during the first quarter. AQR Capital Management LLC now owns 111,079 shares of the company’s stock worth $53,000 after purchasing an additional 86,875 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Century Therapeutics by 26.9% during the first quarter. Goldman Sachs Group Inc. now owns 179,635 shares of the company’s stock worth $86,000 after purchasing an additional 38,052 shares during the last quarter. Acadian Asset Management LLC lifted its stake in Century Therapeutics by 101.2% during the first quarter. Acadian Asset Management LLC now owns 284,229 shares of the company’s stock worth $133,000 after purchasing an additional 142,953 shares during the last quarter. Finally, Prudential Financial Inc. bought a new stake in Century Therapeutics during the second quarter worth $25,000. 50.20% of the stock is currently owned by institutional investors.

Century Therapeutics Price Performance

Shares of NASDAQ:IPSC opened at $2.25 on Wednesday. The company has a market capitalization of $405.80 million, a P/E ratio of -1.97 and a beta of 1.56. Century Therapeutics has a 1 year low of $0.44 and a 1 year high of $3.04. The business’s 50 day simple moving average is $2.27 and its 200 day simple moving average is $1.89.

Century Therapeutics (NASDAQ:IPSC) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. On average, sell-side analysts anticipate that Century Therapeutics will post -0.43 EPS for the current fiscal year.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.